Johnson & Johnson Reaches All-Time High – New Cancer Approval and 50 Billion USD Target Support Growth Story
Reading Time: 3 minutes
The anti-inflammatory drug Tremfya grows by 68%. With ICOTYDE and Shockwave, further growth opportunities arise. Rybrevant Faspro receives another cancer approval. New data show advancements in a prostate cancer immunotherapy. The oncology revenue is growing in double digits and is expected to exceed 50 billion USD by 2030. Johnson & Johnson (JNJ) develops drugs for cancer, inflammatory and nerve diseases, as well as medical technology for heart treatments and surgeries. On November 9, the stock rose by 2.13% to 282.11 USD, briefly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
